Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00296-017-3789-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HLA-DRB1*01 predicts treatment outcome in juvenile idiopathic arthritis: A retrospective-prospective cohort study.
Biomol Biomed
October 2024
Clinical Immunology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory autoimmune disease in childhood, significantly contributing to both short- and long-term disability. While certain human leukocyte antigen (HLA) class II alleles are known to be associated with specific subgroups of JIA, emerging evidence suggests a strong correlation between these alleles and treatment response. This study involved 143 JIA patients diagnosed according to International League of Associations for Rheumatology criteria.
View Article and Find Full Text PDFAre There Disease Endotypes in Axial Spondyloarthritis and How Would We Define Them?
J Rheumatol
December 2024
K.D. Deane, MD, PhD, K.A. Kuhn, MD, PhD, Division of Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado;
Is axial spondyloarthritis (axSpA) one disease or does it comprise multiple types? If the latter, how do we define those types-through clinical or imaging features, HLA-B27 status, or by other immunologic features? Data comparing disease outcomes for individuals with nonradiographic vs radiographic axSpA, or for male vs female patients, demonstrate distinctions. So then, how should we define endotypes? Endotypes are known as the subtype of a health condition defined by a functional or pathophysiologic function. Here, we review the endotypes used for defining rheumatoid arthritis, asthma, and psoriatic arthritis.
View Article and Find Full Text PDFBiologics in ocular inflammatory diseases - Experience from a tertiary referral eye care center in South India.
Indian J Ophthalmol
September 2024
Department of Rheumatology, Manipal Hospitals, Millers Road, Bengaluru, Karnataka, India.
Article Synopsis
- The study evaluated the effectiveness of biologic treatments for noninfectious uveitis and other eye inflammatory diseases in a South Indian population over several years.
- A total of 76 patients, predominantly adults with anterior nongranulomatous uveitis, were analyzed, revealing adalimumab as the most frequently used biologic.
- While biologics led to a significant reduction in flare-ups, their success rates were lower for certain conditions, particularly in younger patients with specific types of uveitis.
Prevalence of HLA-B27, clinical characteristics and treatment outcomes in children with enthesitis-related arthritis.
BMC Pediatr
August 2024
Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
Background: Enthesitis-related arthritis (ERA) is a subtype of juvenile idiopathic arthritis with high disease burden. The objectives of this study were to explore the prevalence of HLA-B27, clinical characteristics, and treatment outcomes in children with ERA and compare the differences between HLA-B27 positive and negative patients.
Methods: A retrospective cohort study at a pediatric rheumatology clinic in a tertiary referral hospital in Bangkok, Thailand, including ERA patients with at least 6 months of follow-up (July 2011-April 2022) was performed.
The Impact of Different MEFV Genotypes on Clinical Phenotype of Patients with Familial Mediterranean Fever: Special Emphasis on Joint Involvement.
Eur J Pediatr
October 2024
Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Türkiye.
Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease worldwide. In this retrospective cohort study, we aimed to assess the effects of various MEFV genotypes on the clinical characteristics of the patients, with a special focus on the joint involvement. In total, 782 patients with FMF were categorized into 3 groups according to the MEFV mutation; Group 1: Patients homozygous for M694V; Group 2: Patients carrying other pathogenic MEFV variants in exon 10 in homozygous or compound heterozygous states; and Group 3: FMF patients with other variants or without mutations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!